VentureMed Group, Inc

VentureMed Group, Inc. develops and markets advanced endovascular medical devices aimed at improving patient outcomes in vascular interventions. Their primary innovation is the Flex Vessel Prep™ System, designed to enhance angioplasty procedures. Founded in 2012, VentureMed Group, Inc.

operates from Plymouth, US, focusing on the creation of medical devices. In October 2025, VentureMed Group, Inc raised USD 28 million in series C funding led by new investor S3 Ventures, with participation from returning investor Endeavour Vision. Other unspecified investors also participated in the round. CEO Robert Paulson oversees the operations, while John Pigott is noted as the founder of the company.

VentureMed Group, Inc. specializes in the development and marketing of innovative endovascular medical devices, primarily focusing on the Flex Vessel Prep™ System. This device optimizes percutaneous transluminal angioplasty (PTA) procedures by addressing significant limitations associated with traditional balloon angioplasty treatments for arteriovenous (AV) access and peripheral arterial disease (PAD). Designed to improve vessel compliance, minimize barotrauma, and create controlled micro-incisions in stenotic lesions, the Flex Vessel Prep™ System enhances luminal gain and reduces complications, serving healthcare providers in North America and Europe, particularly targeting vascular surgery and interventional radiology specialists.

VentureMed Group, Inc. generates revenue through direct sales of its medical devices, notably the Flex Vessel Prep™ System, to healthcare facilities and professionals engaged in vascular interventions. The company employs a B2B transaction structure, with sales occurring through direct orders from hospitals and outpatient centers characterized by bulk purchases. The pricing for the Flex Vessel Prep™ System aligns with industry standards for specialized medical equipment, reflecting its advanced technology and associated patient outcomes, aiming to build long-term partnerships with healthcare providers.

In October 2025, VentureMed Group, Inc raised USD 28 million in series C funding led by new investor S3 Ventures, with participation from returning investor Endeavour Vision and other unspecified investors. The funding will be allocated towards expanding and developing robust clinical data, enhancing the literature database, and increasing scholarly presentations. The company plans to request US reimbursement by January 2024 and generate awareness for its "Disparities in Care" Initiative while demonstrating commercial viability in selected international markets. The company will use the October 2025 funding to expand its commercial infrastructure, advance its clinical program, and develop new products for adjacent vascular applications.